Recent advancements in the management of FLT3-mutated acute myeloid leukemia (FLT3+ AML) have focused on the integration of next-generation FLT3 inhibitors, such as gilteritinib and quizartinib, into frontline and relapsed/refractory treatment settings. Combination therapies with hypomethylating agents and venetoclax show promising efficacy. Emerging data on resistance mechanisms and minimal residual disease (MRD) monitoring further refine therapeutic strategies, emphasizing the importance of personalized treatment approaches and ongoing clinical trials in improving patient outcomes.

The management of acute promyelocytic leukemia (APL) has transformed remarkably with the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). These agents, in combination with chemotherapy or as monotherapy in low-risk patients, have significantly improved survival rates. Prompt diagnosis and initiation of therapy are crucial to address the high risk of early hemorrhagic complications. Molecular monitoring and risk-adapted strategies remain essential for optimizing outcomes in this highly curable leukemia.

Acute myeloid leukemia (AML) presents with substantial heterogeneity, demanding timely, patient-specific decisions to optimize outcomes. In this session, Dr. Catherine Lai will explore the evolving landscape of real-time treatment decision-making in AML, highlighting how genomic data, disease status, and patient characteristics influence therapeutic strategies. Attendees will gain insights into selecting appropriate targets, sequencing novel agents, and integrating biomarkers into clinical practice. Emphasis will be placed on who to treat, when to intervene, and how to personalize approaches for maximum efficacy.

Intensive chemotherapy has long been the backbone of therapy for acute lymphoblastic leukemia (ALL), but long-term toxicities remain a critical concern for younger patients. In this session, Dr. Kristen O’Dwyer will discuss emerging strategies aimed at minimizing chemotherapy exposure while maintaining durable remissions. Topics include the integration of targeted therapies, immunotherapies, and risk-adapted approaches that optimize outcomes and limit treatment-related morbidity. Attendees will gain practical insights into evolving treatment paradigms designed to reduce toxicity, improve quality of life, and enhance survival in younger ALL patients.

Allogeneic hematopoietic stem cell transplantation (HSCT) remains a pivotal curative option in acute lymphoblastic leukemia (ALL), particularly in high-risk and relapsed cases. This talk will explore risk stratification, measurable residual disease (MRD)-guided decisions, timing relative to remission status, and evolving criteria in the era of immunotherapy. Emphasis will be placed on balancing transplant-related morbidity with long-term survival benefits to guide optimal patient selection and timing.

Older adults with acute lymphoblastic leukemia (ALL) present unique therapeutic challenges due to age-related comorbidities, reduced treatment tolerance, and distinct disease biology. This talk will explore personalized strategies that balance efficacy and tolerability, including reduced-intensity chemotherapy, targeted therapies, and supportive care optimization. Advances in immune targeting, molecular profiling and minimal residual disease monitoring are reshaping treatment paradigms. Our focus will be on integrating these innovations to improve survival and quality of life in this vulnerable population.

Chimeric antigen receptor T cell (CAR-T) therapy continues to transform outcomes in relapsed/refractory acute lymphoblastic leukemia (ALL). This session will explore recent advancements including next-generation CAR constructs, strategies to overcome antigen escape, and enhanced safety profiles. We will also discuss emerging data on allogeneic CAR-T products and their clinical implications. These updates mark significant strides toward durable remissions and broader accessibility, reshaping the therapeutic landscape for both pediatric and adult ALL patients.

Best Abstract- Risk of Pulmonary Hypertension in High-Risk Polycythemia Vera: A Retrospective Cohort Study

Best Abstract Recipent- Divya Samat, MD

The discovery of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) from a highly fatal leukemia (median survival 3-6 years) to an indolent one with a 10-year relative survival rate of 90+%. Six BCR::ABL1 TKIs are approved for the treatment of CML, five of them, imatinib, dasatinib, bosutinib, nilotinib, and asciminib as frontline therapy, and all 5 plus ponatinib as later-line therapies. The goals of CML therapy are: 1) Normalize survival: this is achievable with any of the TKIs, provided the patients can afford the TKI, comply with the treatment, are monitored optimally, and can change therapy when resistance develops. 2) Improve the rate of durable (sustained) deep molecular response (DMR = BCR::ABL1 transcripts on the International Scale [IS]

The decision to pursue allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myeloproliferative neoplasms (MPNs) is highly complex, and requires careful assessment of disease risk, patient comorbidities, and transplant-factors such as available stem cell source. In this session, Dr. Juliet Barker will provide a focused, evidence-based overview from the transplanter’s perspective, addressing which patients could potentially derive the most benefit from transplant. She will explore prognostic scoring systems, molecular risk features, and current outcomes data to guide transplant candidacy in both chronic and advanced-phase MPNs. She will also discuss novel strategies under investigation that have the potential to improve the curative potential of allogeneic transplant in these diseases in the future.

Supported by an educational grant from PharmaEssentia USA Corporation.

Learning Objectives: • Integrate the latest clinical trial data, real-world evidence, and practice guidelines to effectively differentiate, diagnose, and manage ET and PV • Assess the MOAs and the safety and efficacy profiles of newer and emerging targeted therapies for managing ET and PV to prevent disease progression • Implement multidisciplinary, patient-centered strategies that leverage PROs to manage TRAEs, assess symptoms, and reduce cardiovascular risk

Aplastic anemia remains a rare but serious hematologic disorder that demands timely recognition and precise therapeutic intervention. This session will highlight recent advancements in the understanding of pathophysiology, diagnostic workup, and novel treatment paradigms, including immunosuppressive regimens and stem cell transplantation. Dr. Amy DeZern, a leading expert in bone marrow failure syndromes, will share her insights on current clinical approaches and the shifting landscape of care in 2025. Clinicians will gain clarity on navigating emerging therapies and optimizing outcomes in both newly diagnosed and relapsed patients.

Patient-derived xenograft (PDX) models have become indispensable tools in lymphoma research, enabling preclinical evaluation of therapeutic strategies in a biologically relevant context. This session will examine how PDX systems are being leveraged to dissect lymphoma pathogenesis, predict treatment response, and accelerate drug development. Dr. Giorgio Inghirami will share key findings from ongoing research, highlighting the role of PDX in bridging laboratory discoveries with clinical application. Attendees will gain a deeper appreciation of how these models are shaping the future of personalized lymphoma therapy.

The relationship between Epstein-Barr virus (EBV) and lymphoma continues to spark critical questions in both research and clinical practice. This session will explore the role of EBV in the pathogenesis of various lymphoma subtypes, its diagnostic implications, and emerging strategies targeting EBV-driven disease. Dr. Lisa Roth will provide expert insights into how EBV status influences prognosis and treatment decisions. Clinicians will come away with a clearer understanding of when EBV matters—and how it can inform therapeutic approaches.

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in lymphoma, offering insights into underlying disease biology at diagnosis as well as response assessment, particularly for assessing measurable residual disease (MRD) status. This session will review current evidence supporting the clinical utility of ctDNA across lymphoma subtypes and highlight ongoing efforts to standardize its application. Dr. Russler-Germain will discuss key developments in ctDNA assay technology and their translational implications. He will highlight novel clinical trial designs that incorporate ctDNA testing, explain how ctDNA testing can accelerate drug development, and outline existing standard-of-care uses for ctDNA testing. Attendees will gain a forward-looking view of how ctDNA is shaping precision medicine in lymphoma care.

Despite remarkable advances in targeted and cellular therapies, lymphoma remains a disease where durable immune control is often elusive. Vaccine-based immunotherapy, once a promising but unrealized strategy, is experiencing a renaissance driven by advances in neoantigen discovery, dendritic cell engineering, and combinatorial checkpoint blockade. Dr. John Timmerman will review the historical evolution of lymphoma vaccines, examine lessons learned from prior clinical trials, and highlight emerging platforms poised to reinvigorate this therapeutic modality. The session will explore how precision immunology and personalized vaccines may finally bring vaccine therapy for lymphoma “back to the future.

Extranodal marginal zone lymphomas, including mucosa-associated lymphoid tissue (MALT) lymphomas, present with a wide range of clinical behaviors that demand individualized management strategies. This session will explore how to determine when observation is appropriate, when localized radiotherapy is optimal, and when systemic therapy should be pursued. Dr. Leo Gordon will share his expert insights on tailoring treatment based on disease site, burden, and progression risk. Attendees will leave with a clearer framework for managing this indolent yet complex group of lymphomas.

Cutaneous lymphomas represent a diverse group of extranodal non-Hodgkin lymphomas with distinct clinical behaviors and therapeutic challenges. This session will focus on the most common type of cutaneous lymphoma, mycosis fungoides. Current approaches to diagnosis, staging, and treatment selection, with an emphasis on integrating dermatologic and oncologic care will be discussed. Dr. Alison Moskowitz will highlight evolving strategies, including skin-directed therapies, systemic options, and emerging biologics. Participants will gain practical insights into optimizing management and improving outcomes for patients with cutaneous lymphomas.

The initial management of follicular lymphoma has evolved significantly, with growing emphasis on risk-adapted strategies and long-term disease control. Dr. Jonathan Friedberg will address the question of whether cure is a realistic goal in this historically incurable disease by reviewing the long-term follow-up of studies using standard approaches in the contemporary era, including observation, immunochemotherapy, and novel agents. Attendees will also look ahead to the incorporation of novel approaches into the treatment paradigm.

Supported by an educational grant from AstraZeneca.

Learning Objectives: Describe best practices in the diagnostic evaluation of R/R FL to accurately confirm disease status and detect disease progression or histologic transformation Evaluate the current treatment landscape and the latest clinical trial data on approved and emerging treatments for R/R FL Apply interdisciplinary strategies to personalize treatment plans for R/R FL patients, considering disease characteristics, prior therapies, and individual patient factors

Best Abstract Title: Comparative Real-World Outcomes of CAR-T Therapy in Elderly (≥70 Years) Versus Younger (

B cell lymphomas comprise a diverse group of malignancies that continue to present significant clinical challenges due to their heterogeneity, resistance mechanisms, and variable responses to therapy. In recent years, advances in genomic profiling, epigenetics, tumor microenvironment studies, and immunotherapeutics have dramatically reshaped our understanding of B cell lymphomagenesis. The future of treatment lies in the integration of science-driven strategies that leverage these insights to deliver more precise, personalized, and durable therapies. This session will explore emerging approaches grounded in cutting-edge biology, including targeted inhibition of oncogenic pathways, epigenetic reprogramming, and rational combinations of small molecules and immunotherapies. Particular focus will be given to mechanisms of resistance and relapse, and how these can be anticipated and overcome through biomarker-driven interventions. Dr. Ari Melnick, a leading figure in the molecular biology of lymphoid malignancies, will share pioneering work on the transcriptional and epigenetic circuitry of B cell development and transformation. His research has led to the identification of critical vulnerabilities in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma, informing novel therapeutic strategies now entering clinical translation. By anchoring clinical innovation in molecular science, the next era of B cell lymphoma management promises not only better outcomes but a fundamental shift in how these complex cancers are understood and treated.

The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) continues to evolve, with CAR-T cell therapy offering new hope for select patients. In this dynamic debate, Dr. Catherine Diefenbach will focus on identifying appropriate CAR-T candidates and optimizing outcomes through cellular therapy. Dr. Jeremy Abramson will address evidence-based strategies for patients ineligible for, or without access to, CAR-T therapy, including novel agents and palliative approaches. This session will provide a balanced, practical discussion of real-world treatment pathways for a challenging disease.

Supported by an educational grant from Bristol-Myers Squibb

Learning Objectives: • Describe the safety and efficacy, mechanisms of action, and key clinical data for available and emerging CAR T-cell therapies in R/R DLBCL • Evaluate precision medicine-based and personalized treatment strategies regarding CAR T-cell therapies that best address individual DLBCL patient needs and risk profiles • Incorporate molecular and genetic techniques, such as minimal residual disease monitoring and next-generation sequencing, as appropriate, into individualized R/R DLBCL treatment plans

Limited stage Hodgkin lymphoma presents a unique opportunity for curative therapy with a careful balance between efficacy and long-term toxicity. This session will explore current strategies for staging, risk assessment, and integrating chemotherapy with or without radiation. Dr. Astrid Pavlovsky will share her approach to tailoring treatment based on patient characteristics and evolving clinical data, integrating the expertise of a multidisciplinary team before making final treatment decisions. Attendees will explore the potential role for new drugs in local-stage Hodgkin lymphoma and gain practical insights into optimizing outcomes while minimizing late effects in early-stage disease.

Managing Hodgkin lymphoma in older adults requires a nuanced approach that balances curative intent with comorbidities, functional status, and treatment tolerance. This session will review key considerations in tailoring therapy, including the role of modified regimens, supportive care strategies, and novel agents. Dr. Sarah Rutherford will share her clinical framework for optimizing outcomes in this often underrepresented patient population, and attendees will gain practical guidance on delivering effective and compassionate care to older individuals with Hodgkin lymphoma.

Supported by educational grants from Daiichi Sankyo and Secura Bio.

Learning Objectives: • Describe the current limitations of standard therapies for PTCL and identify key molecular subtypes that may guide future treatment strategies • Evaluate emerging therapeutic approaches in PTCL, including epigenetic modulators, PI3K inhibitors, and ADCs, in the context of ongoing clinical trials and biomarker research • Integrate knowledge of novel and investigational agents into evidence-informed decision-making for patients with R/R or high-risk PTCL

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) present diagnostic and management challenges, particularly in identifying which patients are at high risk for progression. This session will explore evolving risk stratification models, biomarkers, and early intervention strategies that are redefining the standard of care. Dr. Irene Ghobrial will provide expert insights into the latest clinical trials and evidence guiding decisions on surveillance versus treatment. Participants will gain a clearer framework for managing precursor plasma cell disorders in 2025.

Accurately identifying which patients with precursor conditions such as MGUS or smoldering myeloma will progress to active disease remains a critical challenge in plasma cell dyscrasias. This session will delve into emerging biomarkers, genomic signatures, and imaging tools that enhance risk prediction and guide early intervention strategies. Dr. Sagar Lonial will discuss the latest evidence and clinical implications of incorporating these biomarkers into practice. Attendees will gain valuable insights into stratifying risk and refining surveillance in at-risk patient populations.

Supported by an education grant from Johnson & Johnson.

Learning Objectives: Describe the significance of risk stratification, transplant-eligibility, and MRD status when considering optimal frontline therapy and subsequent treatment sequencing for the patient with MM Evaluate the most recent clinical trial data, evidence-based guidelines, and treatment implications associated with novel and emerging MM frontline therapies Assess and implement effective strategies to mitigate and/or manage AEs and address therapeutic resistance in MM treatment regimens to improve QoL and survival outcomes

Advances in genomic profiling are transforming the management of multiple myeloma, enabling more precise risk stratification and targeted therapeutic decisions. This session will explore how real-time genomic data is being integrated into clinical workflows to personalize treatment and monitor disease evolution. Dr. Mark Bustoros will highlight key genomic alterations, their clinical relevance, and the practical tools available to implement precision medicine at the bedside. Participants will gain a forward-looking view of how genomics is reshaping the care paradigm for myeloma patients.

Therapeutic resistance in heavily pretreated hematologic malignancies presents a growing challenge as patients cycle through multiple lines of therapy. This session will examine mechanisms of resistance and highlight emerging strategies to re-establish disease control, including novel agents, combination regimens, and cellular therapies. Dr. Cristina Gasparetto will share her clinical experience and insights into managing complex, refractory cases with an eye toward maximizing efficacy while preserving quality of life. Attendees will gain practical guidance on navigating this high-risk patient population with evolving therapeutic tools.

The future of myeloma immunotherapy is rapidly expanding beyond B cell maturation antigen (BCMA), with a growing array of novel antigens and next-generation targets under investigation. This session will highlight the most promising candidates, including GPRC5D, FcRH5, and others, along with the evolving platforms designed to exploit them. Dr. Ola Landgren will provide an expert overview of the scientific rationale, clinical data, and translational potential of these emerging strategies. Attendees will gain valuable insight into the next wave of innovation poised to reshape myeloma treatment.

The therapeutic landscape of relapsed multiple myeloma is being redefined by next-generation immunomodulatory drugs (IMiDs) and cereblon E3 ligase modulators (CELMoDs). These novel agents offer enhanced potency, distinct mechanisms of action, and promising activity in patients with prior exposure to conventional therapies. Dr. Nikhil Munshi will discuss the latest clinical data, mechanistic insights, and practical considerations for integrating these agents into treatment regimens. This session will highlight how these advancements are reshaping outcomes in relapsed and refractory myeloma.

The treatment of multiple myeloma (MM) has been revolutionized over the past three decades, first with the introduction of high-dose melphalan and autologous stem cell transplantation (ASCT) for younger, fitter patients, and then with the development and approval of 20 novel agents and multiple combination regimens within the past 22 years. From a historically poor prognosis, with a median overall survival of only approximately 3-5 years, the outlook for patients with newly diagnosed MM has been transformed by these new targeted treatment options, with median overall survival now more than 10 to 15 years for younger transplant-eligible patients and more than 7 to 10 years for older transplant-ineligible patients. Critical developments in evolving the MM treatment paradigm have included the preclinical evaluation and widespread introduction of novel drug classes such as the proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), the immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), and the CD38 and SLAMF7 monoclonal antibodies (daratumumab, isatuximab, elotuzumab), which together now form the backbone of treatment in the newly diagnosed and relapsed/refractory settings in highly active rational combination regimens. Indeed, first highly active triple and then quadruplet regimens based on lenalidomide, bortezomib or carfilzomib, and dexamethasone with the addition of daratumumab or isatuximab, are emerging as the standards of care for transplant-eligible and transplant-ineligible patients with newly diagnosed MM, offering high rates of minimal residual disease (MRD)-negative responses and prolonged clinical outcomes; in this context, the role of high-dose melphalan and ASCT has evolved, with highly effective induction therapy enabling deferred- or non-transplant approaches for selected transplant-eligible patients in the upfront setting, now further enhanced by the use of MRD. Furthermore, building on our knowledge of MM cell biology, a wide range of additional novel signalling pathways and antigens have been explored and targeted through the development and approval of agents including the histone deacetylase inhibitor panobinostat, the XPO1 inhibitor selinexor, the peptide–drug conjugate melflufen, B-cell maturation antigen (BCMA)-targeting therapies such as the antibody–drug conjugate belantamab mafodotin, the CAR T-cell therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel, and the bispecific antibodies teclistamab, elranatamab, and linvoseltamab, and the G protein–coupled receptor class C group 5 member D (GPRC5D)-targeted bispecific antibody talquetamab. A wealth of additional options are also currently under investigation, including the cereblon E3 ligase modulators iberdomide and mezigdomide, CAR T-cell therapies and bispecific antibodies targeting novel MM-associated antigens, and novel targeted therapies exploiting immune-based mechanisms and specific signalling pathways of importance for MM cell survival. Together, these developments have converted our extensive exploration and translation of MM cellular pathobiology and mechanisms of resistance into an armamentarium of therapeutic options for today’s physicians and providers, and in doing so have transformed outcomes for our patients with this highly complex and previously incurable disease.

The success of CAR T-cell and other adoptive cellular therapies in relapsed and refractory hematologic malignancies has prompted investigation into their use earlier in the disease course. Dr. Natalie Callander will discuss evolving data supporting the integration of cellular therapies in earlier treatment lines for lymphoma, myeloma, and leukemia. The session will address patient selection, toxicity management, manufacturing and access challenges, and comparative outcomes with standard regimens. As next-generation constructs and allogeneic platforms emerge, this presentation will critically evaluate whether the field is truly ready to move cellular therapies forward in the treatment paradigm.

Bispecific antibodies have rapidly emerged as transformative agents in the management of hematologic malignancies, bridging tumor and immune cells to achieve potent anti-tumor activity. Dr. Noopur Raje will review recent clinical trial data and expanding real-world experience with bispecific antibodies in multiple myeloma and related disorders. The session will highlight efficacy, safety, and management of unique toxicities such as cytokine release syndrome and neurotoxicity, as well as strategies for sequencing and combination approaches. Attendees will gain practical insights into integrating bispecific antibody therapies into clinical practice and understanding their evolving role in the modern treatment landscape.

CAR T-cell therapies and bispecific antibodies are now critical treatments relapsed and refractory myeloma but questions around optimal sequencing remain. How does the clinician choose between all of these options? Furthermore, those choices are often guided by safety concerns. How do we match the therapy to the patient to deliver these therapies effectively, safely and conveniently to patients? Dr. Joseph Mikhael will provide expert insights on making these decisions by maximizing therapeutic benefit while navigating toxicities. Attendees will come away with practical strategies for integrating these powerful immunotherapies into real-world care.

T cell-directed therapies, including bispecific antibodies and CAR-T cell treatments, have transformed outcomes in hematologic malignancies but are associated with a unique and sometimes severe toxicity profile. This session will focus on the identification and management of key toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and prolonged cytopenias. Dr. Adriana Rossi will share practical strategies and clinical pearls for anticipating, mitigating, and managing these complications across care settings. Attendees will leave better equipped to deliver safe and effective T cell therapies while minimizing treatment-related morbidity.

Supported by an education grant from Johnson & Johnson.

Learning Objectives: Evaluate the clinical and individual factors influencing access to and treatment planning for BCMA-directed CAR T-cell therapy in R/R MM Assess the latest clinical trial and emerging data that inform patient selection, therapeutic bridging strategies, and sequencing of BCMA-directed CAR T-cell therapies in R/R MM Describe evolving best practices for the care of patients undergoing CAR T-cell therapy, emphasizing interdisciplinary care coordination, shared decision-making, and the early identification and mitigation of treatment-related AEs

Despite remarkable progress in the treatment of chronic lymphocytic leukemia (CLL), important questions remain regarding long-term disease control, resistance mechanisms, and curative potential. This session will examine the current frontiers in CLL research, from optimizing sequencing of targeted agents to uncovering biomarkers that refine risk and guide individualized care. Dr. Richard Furman will explore the unanswered clinical and scientific questions that continue to drive innovation in CLL management. Attendees will gain insight into where the field is headed and what gaps must still be addressed to further improve patient outcomes.

The 2025 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) showcased groundbreaking advances in the biology, prognostication, and treatment of CLL. This session will highlight the most impactful clinical trial data, novel therapeutic strategies, and evolving standards of care presented at the meeting. Dr. Richard Furman will provide expert analysis and perspective on how these developments are shaping the future of CLL management. Attendees will gain a timely and comprehensive overview of the latest progress in the field.

Supported by education grants from AstraZeneca and BeOne.

Learning Objectives • Describe the most recent clinical data and real-world evidence associated with approved and emerging novel targeted therapies for CLL/SLL • Evaluate tailored approaches to CLL management in the context of risk stratification, available treatment options, current recommended guidelines, and patient characteristics and preferences to optimize outcomes • Summarize the importance of MRD evaluation and molecular profiling for treatment selection and sequencing in CLL/SLL

Richter transformation remains a serious complication in patients with chronic lymphocytic leukemia (CLL), often leading to poor outcomes despite aggressive treatment. This session will explore the clinical, molecular, and genetic risk factors associated with the development of Richter transformation, as well as novel treatment approaches currently being explored in the clinic. Dr. Matthew Davids will review current evidence and discuss how emerging biomarkers may improve early identification, risk stratification, and ultimately treatment outcomes. Attendees will gain valuable insight into the evolving landscape of the biological risk factors and new treatment approaches for this disease.

The emergence of non-covalent Bruton tyrosine kinase inhibitors (BTKi’s) represents a major advancement in the treatment of B-cell malignancies, offering potent activity in patients with resistance or intolerance to covalent BTKi therapy. Dr. Nicole Lamanna will review the evolving clinical data on next-generation agents, including their mechanisms of action, efficacy across disease settings, and unique safety profiles. The session will also explore resistance biology, sequencing strategies, and real-world considerations in integrating these therapies into practice. Attendees will gain a clear understanding of where non-covalent BTKi’s fit within the rapidly changing therapeutic landscape of chronic lymphocytic leukemia and related disorders.

While CAR-T cell therapy has revolutionized treatment in other B cell malignancies, its role in chronic lymphocytic leukemia (CLL) is still being defined. This session will explore the latest data on CAR-T cell efficacy in CLL, patient selection criteria, and how to navigate challenges such as T cell dysfunction and high-risk disease biology. Dr. Stephen Schuster will provide expert insights into when and how to deploy CAR-T therapy in the CLL treatment landscape. Attendees will gain a clear framework for incorporating this powerful modality into clinical practice for appropriately selected patients.

Autoimmune complications, including autoimmune hemolytic anemia and immune thrombocytopenia, are common and clinically significant in chronic lymphocytic leukemia (CLL). This session will review the pathophysiology of CLL-associated autoimmunity, its impact on disease course, and strategies for diagnosis and management. Dr. Jennifer Brown will share insights on how evolving therapies may influence autoimmune risk and how to tailor treatment in affected patients. Attendees will gain practical knowledge for addressing this complex and often underrecognized aspect of CLL care.

Measurable residual disease (MRD) has emerged as a powerful prognostic and potentially predictive tool in chronic lymphocytic leukemia (CLL), offering guidance for treatment duration and monitoring. This session will explore the evolving role of MRD assessment in both clinical trials and real-world practice, including its integration with targeted therapies. Dr. Neil Kay will provide expert insights into interpreting MRD results and applying them to individualized patient care. Attendees will gain a practical framework for using MRD to inform therapeutic decisions and long-term management in CLL.

Waldenström macroglobulinemia (WM) is an incurable but manageable B-cell malignancy defined by IgM monoclonal protein, bone marrow infiltration, and recurrent MYD88 and CXCR4 mutations. Biology strongly influences presentation, prognosis, and treatment response. Emerging data highlight the role of TP53 and other mutations in resistance. Clinical trials of novel BTK inhibitors, degraders, and combinations with BCL2 inhibitors show promise. Tailoring therapy to molecular and clinical risk factors remains central to improving outcomes in WM